{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-034618","form_type":"8-K","ticker":"SONM","cik":"0001178697","company_name":"DNA X, Inc.","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.322107+00:00","generated_at":"2026-06-10T07:26:42.309407+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sonim shareholders approve 2M-share increase to 2019 equity plan","bullets":["Shareholders approved amendment to 2019 Equity Incentive Plan to add 2,000,000 authorized shares (21,214,229 for, 2,361,341 against).","Total share reserve under the plan now 11,003,242, plus automatic annual evergreen increases through 2029.","All five director nominees (Cassano, Liu, Mulica, Steenstra, Wang) elected at annual meeting.","Plan amendment effective September 28, 2023; enables continued equity grants to employees, directors, and consultants."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-034618","json":"https://secwatch.observer/filing/0001493152-23-034618.json","markdown":"https://secwatch.observer/filing/0001493152-23-034618.md","text":"https://secwatch.observer/filing/0001493152-23-034618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178697/000149315223034618/0001493152-23-034618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178697/000149315223034618/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:26:42.309407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e3ae08e046d2dc21a0dbf80caa1878a835e4414","claim":"DNA X, Inc. shareholders approved Election of five director nominees to the Board of Directors at the 2023-09-28 meeting.","evidence_excerpt":"The Annual Meeting was held on September 28, 2023. Holders of 30,394,319 shares of the Company’s common stock were represented at the meeting in person or by proxy, constituting a quorum. The following are the voting results on each matter submitted to the stockholders of the Company at the Annual Meeting. Proposal 1: The stockholders elected each of the five director nominees to the Board of Directors of the Company to serve until the next annual meeting and until his or her successor has been duly elected and qualified, as follows: Name Votes Withheld Broker Non-Votes James Cassano 22,559,091 1,040,013 6,795,215 Peter Liu 23,452,354 153,953 6,788,012 Mike Mulica 21,565,460 2,040,805 6,788,054 Jack Steenstra 21,547,809 2,051,253 6,795,257 Jeffrey Wang 23,399,954 206,353 6,788,012","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315223034618/0001493152-23-034618-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-28"}],"fact_type":"shareholder_vote"},{"claim_id":"47fbe8d4c0d2a969c1d18249a938a988ce6779fd","claim":"DNA X, Inc. shareholders approved Approval of amendment to the Plan to increase aggregate number of shares of common stock authorized for issuance by 2,000,000 shares at the 2023-09-28 meeting.","evidence_excerpt":"Proposal 3: The stockholders approved an amendment to the Plan to increase the aggregate number of shares of common stock authorized for issuance by 2,000,000 shares, as follows: Votes Against Votes Abstained Broker Non-Votes 21,214,229 2,361,341 30,737 6,788,012","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315223034618/0001493152-23-034618-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-28"}],"fact_type":"shareholder_vote"},{"claim_id":"50517b8f9e879a4726f55146ba42c47ff6a1a3e1","claim":"DNA X, Inc. shareholders approved Ratification of appointment of Moss Adams LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-09-28 meeting.","evidence_excerpt":"Proposal 2: The stockholders, on an advisory basis, ratified the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, as follows: Votes Against Votes Abstained Broker Non-Votes 30,231,684 137,903 24,732 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315223034618/0001493152-23-034618-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-28"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}